Health software companies are usually judged on two things: whether hospitals keep signing, and whether the cash finally arrives. Alcidion Group (ASX:ALC) has spent years on the first and, on recent disclosure, has started to deliver the second. The Melbourne-based developer of the Miya Precision clinical platform reported record Operating Cash Flow in the June 2026 quarter, added a patient flow product suite by acquisition, and secured a long-dated contract with a British NHS trust. With a Market Value near A$141.72 million as of 14 September 2026, it sits in the small end of the ASX health care sector.

Latest Development

The most significant recent step is in the United Kingdom. Alcidion's own news material, accessed on 11 September 2026, records that University Hospitals Sussex NHS Foundation Trust has signed a seven-year contract with the company. Market data compiled by Small Caps and accessed the same day describes Alcidion being named preferred electronic patient record supplier to a UK NHS trust, with contracts potentially worth more than A$35 million across seven years.

For a company of Alcidion's size, a multi-year electronic patient record engagement matters less for its headline value than for the reference it creates in NHS procurement.

Company Overview

Alcidion listed on the ASX on 24 June 2011 and is headquartered in South Yarra, Victoria. It develops and licenses healthcare software, led by Miya Precision, a FHIR-event platform supporting a range of clinical and operational applications and associated modules.

It also resells third-party healthcare software and earns fees from implementation, support, maintenance, systems integration and data analysis. Its customer base spans Australia, New Zealand and the United Kingdom, giving it exposure to three separate public health procurement cycles.

Recent Developments

Alcidion acquired the Kyra suite from Telstra Health for A$3 million, adding Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ to its patient flow business. Miya Precision also achieved dual Class I software as a medical device registrations in Australia and the United Kingdom for its concept detection capability.

Deployments cited by the company include Miya Emergency at University Hospital Southampton, remote patient monitoring with Gold Coast Health, and an implementation at Herefordshire and Worcestershire Health and Care NHS Trust, where average patient stays reportedly fell by roughly five days.

What Investors May Watch Next

Conversion of the Sussex engagement into recognised revenue, further NHS tenders and integration of the Kyra products are the clearest checkpoints. Quarterly cash flow reports will show whether the June result was a peak or a sustainable level, and contract renewals across the Australian and New Zealand base remain relevant.

Risks

Public health software Revenue is lumpy and tied to government budget cycles in three countries, so timing can slip without any change in demand. Electronic patient record implementations are long and reputationally sensitive. The company remains exposed to far larger international vendors, to currency movements on UK earnings, and to the execution risk of absorbing an acquired product set.

Key Takeaways

What could put Alcidion on investor radars in September 2026 is the combination of a signed seven-year NHS contract, a record quarterly cash result and a bolt-on Acquisition aimed at the patient flow niche it already serves. Each is verifiable; none assures the next. The outlook may depend on whether the company can repeat that cash performance while carrying the cost of a major UK deployment.